胶质母细胞瘤当代进展:分子生物学、当前治疗与面向生物适应性个体化治疗的愿景
该综述回顾已发表文献,讨论胶质母细胞瘤(GBM)生物学与治疗现状,并总结可能指向未来个体化治疗策略的信息。文章指出已引入溶瘤病毒、靶向免疫与分子治疗、肿瘤电场治疗等新方式,但目前尚无单一治疗模式,现有文献也缺乏通向个体化GBM治疗的成功进展。
要点
- GBM仍是成人最致命脑肿瘤,当前生存率仍低于2年。
- 已有溶瘤病毒、靶向免疫与分子治疗、肿瘤电场治疗等新方式。
- 目前无单一治疗模式,需联合多种方式应对瘤内细胞与遗传异质性。
核心结论
- 当前文献缺乏通向个体化GBM治疗的成功进展,但新治疗方式与联合策略为未来个体化与适应性管理提供方向。
研究设计与样本
- 综述:回顾已发表文献,讨论GBM生物学与治疗现状,并总结可能指向未来个体化治疗策略的信息。
主要发现
- GBM当前生存率仍低于2年,与侵袭性细胞迁移和遗传驱动的治疗逃逸通路有关。
- 尽管对GBM生物学认识增加、诊断更早、手术技术改进,生存获益仅为中等。
- 已引入溶瘤病毒、靶向免疫与分子治疗、肿瘤电场治疗等新方式。
- 目前无单一GBM治疗模式,而是针对瘤内细胞与遗传变异性的多种联合模式。
临床怎么用
- 临床应认识GBM需多模式联合治疗,并关注瘤内细胞与遗传异质性对治疗逃逸的影响。
局限性
- 综述指出当前文献缺乏通向个体化GBM治疗的成功进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Glioblastoma (GBM) is the most fatal brain tumor in adults. Current survival rates of GBM remain below 2 years due to GBM's aggressive cellular migration and genetically driven treatment escape pathways. Despite our rapidly increasing understanding of GBM biology, earlier diagnoses, and refined surgical techniques, only moderate survival benefits have been achieved. Nonetheless, the pressing need for better survival rates has brought forward a multitude of newer therapeutic approaches and opened the door for potential personalization of these modalities in the near future. METHODS: We reviewed the published literature discussing the current state of knowledge regarding GBM biology and therapy and summarized the information that may point toward future personalized therapeutic strategies. RESULTS: Several novel modalities such as oncolytic viruses, targeted immune, and molecular therapies, and tumor treating fields have been introduced. To date, there is no single treatment modality for GBM, but rather a wide spectrum of combined modalities that address intratumoral cellular and genetic variabilities. While the current state of GBM research and clinical trial landscape may hold promise, current literature lacks any fruitful progress towards personalized GBM therapy. CONCLUSION: In this review, we are discussing our recent knowledge of the GBM genetic biologic landscape and the current advances in therapy, as well as providing a blueprint for an envisioned GBM management paradigm that should be personalized and adaptable to accommodate each patient's diverse genetic variations and therapy response/escape patterns.
引用
- Habib A, Pease M, Kodavali CV, et al. A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care. J Neurooncol. 2021. PMID: 33394264. doi:10.1007/s11060-020-03671-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。